Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose
A study of over 600,000 U.S. veterans suggests that GLP-1 weight-loss drugs like Ozempic and Wegovy may reduce the risk of substance use disorders and overdoses. Researchers observed lower rates of addiction-related issues among patients taking these medications for diabetes or weight management.
Why it matters
If confirmed, these findings could expand the therapeutic use of GLP-1 drugs to treat addiction, potentially addressing a major public health crisis.
Popular GLP-1 drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have already transformed the treatment of type 2 diabetes and obesity. Now, new research suggests these medications may also help prevent and treat addiction across a broad range of substances.
The article reports on scientific findings from a specific study without editorializing or promoting the drugs.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in